Approximately 80% of patients with advanced cancer experience cachexia, with a one-year mortality rate of 20% to 60%. However, there are no FDA-approved medications to treat the condition. In a session about facing challenging nutritional scenarios in oncology patients, held at the ASPEN 2025 Nutrition Science & Practice Conference, in Columbus, Ohio, experts outlined available treatments for the wasting syndrome.
As cachexia continues to progress, it impedes patients’